Inventor · disambiguated record
Gavin Halbert
Also filed as: HALBERT GAVIN · HALBERT GAVIN W · HALBERT GAVIN WILLIAM
3 granted patents·10 pending applications·8 citations·filing 1997–2023
62Inventor score
Top patents by PatentIndex Score
13 records- 0175US7276537B2Formulations of anthraquinone derivativesBTG INT LTD·Filed 2006·Granted Oct 2, 2007·3 cites·14 claims
- 0258US7074835B2Formulations of anthraquinone derivativesBTG INT LTD·Filed 2003·Granted Jul 11, 2006·2 cites·18 claims
- 0353US2025122303A1Treatment and prevention of cancer using her3 antigen-binding moleculesHUMMINGBIRD BIOSCIENCE PTE LTD·Filed 2022·Application pending·0 cites
- 0451US2024092018A1Integrated Additive Manufacturing Apparatus and MethodUNIV STRATHCLYDE·Filed 2022·Application pending·0 cites
- 0548US2004235730A1Non-naturally occurring lipoprotein particleUNIV STRATHCLYDE·Filed 2003·Application pending·0 cites
- 0648US2023090337A1Pharmaceutical formulations comprising 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1 -yl)-2-(1,3-dimethyl-1 hpyrazol-4-yl)-3h- imidazo[4,5-b]pyridineELLIPSES PHARMA LTD·Filed 2021·Application pending·0 cites
- 0746US2007166317A1MicroparticlesHALBERT GAVIN W·Filed 2004·Application pending·0 cites
- 0845US2023105181A1Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridineELLIPSES PHARMA LTD·Filed 2021·Application pending·0 cites
- 0943US2007224658A1Cell GrowthHALBERT GAVIN W·Filed 2004·Application pending·0 cites
- 1042US2025196078A1Apparatus for supplying a particulate materialUNIV STRATHCLYDE·Filed 2023·Application pending·0 cites
- 1141US2007027136A1Formulations of anthraquinone derivativesHALBERT GAVIN W·Filed 2004·Application pending·0 cites
- 1240US2012059148A1Non-naturally occurring lipoprotein particleHALBERT GAVIN WILLIAM·Filed 2011·Application pending·0 cites
- 1326US6670452B2Non-naturally occurring lipoprotein particleUNIV STRATHCLYDE·Filed 1997·Granted Dec 30, 2003·3 cites·12 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →